Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

59.81 +1.37 (+2.34%)
Delayed Quote Updated: 1:53 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
News headline image
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
News headline image
Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript ↗
EXEL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis: Q3 Earnings Insights ↗
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis... 
Via Benzinga
News headline image
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Here's My Top Value Stock To Buy Right Now ↗
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Down 76%: Is Cortexyme Stock a Bargain? ↗
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial. 
Via The Motley Fool
News headline image
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Exelixis, Inc.
Via Business Wire
News headline image
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock ↗
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
News headline image
More Chinese Trouble ↗
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
News headline image
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation ↗
The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
News headline image
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2% ↗
Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after recording losses in the previous session. Investors are awaiting earnings results from... 
Via Benzinga
News headline image
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery ↗
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal... 
Via Benzinga
News headline image
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
Both have underperformed the market recently. And both are primed for a comeback. 
Via The Motley Fool
News headline image
Exelixis Statement on the Passing of Two Senior Executives
From Exelixis, Inc.
Via Business Wire
News headline image
Is Exelixis Stock a Buy? ↗
This biotech stock is down, but it's not out just yet. 
Via The Motley Fool
News headline image
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received... 
Via Benzinga
News headline image
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9... 
Via Benzinga
News headline image
Exelixis, Invenra Expand Oncology Pact ↗
Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented... 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.